Integrated, Flexible, and Scalable WorkflowĪnalyze all key biomarkers in a single, verified workflow using the DRAGEN Bio-IT Platform for secondary analysis (now available on-premise or via the cloud with ICA, Illumina Connected Analytics) and Pierian Clinical Genomics Workspace (CGW) for a final interpretation report. With content including current and emerging biomarkers, plus an IVD roadmap in partnership with several pharmaceutical companies, these assays are made to stay in a lab for the long run. Implement the assay in your own lab, to better serve your local community, maintain control of sample and data, and become an active part of the molecular tumor board. Including all key genomic variants, plus the immuno-oncology biomarkers MSI and TMB (emerging), our assays enable a lab to consolidate several independent assays and workflows into a single one, at the same time saving sample, time, and money. Assess all key biomarkers in guidelines, as well as clinical trials, increasing the chances of finding a positive biomarker for every sample.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |